Infliximab clearance was found to be increased in IBD patients with high (>120 kg) and low (<40 kg) body weight (38), which suggests that an appropriate volume of VF maintained the proper concentration of anti-TNF antibody in CD patients. This evidence concerns the gene TNF and inflammatory bowel disease.